Supo-Aromasin 25mg/tab 50 Tabletten by Beligas Pharmaceuticals

Usage

1. Obtain baseline bloodwork — measure serum estradiol, LH, FSH, and total testosterone before starting PCT to establish a reference point for monitoring Exemestane's effect.
2. Calculate PCT start timing — allow the anabolic compound to clear (24–72 h for short esters, 10–14 days for long esters) before taking the first Supo-Aromasin tablet.
3. Take each tablet orally with a fat-containing meal — dietary fat increases Exemestane's oral bioavailability by approximately 40 % above fasted absorption, improving dose consistency across PCT weeks.
4. Adhere to the every-other-day schedule — daily dosing risks over-suppression of estradiol, which impairs LH pulsatility and libido; alternate-day use leverages Exemestane's irreversible mechanism for sustained suppression.
5. Combine with a SERM as directed by your PCT protocol — Exemestane corrects circulating estrogen; a SERM such as Tamoxifen or Clomiphene then stimulates gonadotropin release from the now-uninhibited pituitary.
6. Re-test bloodwork at PCT week 3 and again 2 weeks post-PCT — use estradiol and testosterone values to confirm normalisation and decide whether to taper or discontinue the Exemestane dose schedule.

Warnings

Frequently asked questions

When exactly should I start taking Exemestane during post-cycle therapy?

Timing depends on the half-life of the last compound used. For short-ester cycles, PCT should begin 24–72 hours after the final injection; for long-ester cycles, allow 10–14 days for clearance before initiating. Supo-Aromasin is typically introduced at the start of PCT to correct elevated estrogen before SERM therapy — such as Tamoxifen or Clomiphene — can stimulate LH/FSH recovery effectively.

Why choose an aromatase inhibitor rather than a SERM alone for post-cycle recovery?

SERMs block estrogen at receptors but do not reduce circulating estrogen levels. If estradiol remains elevated post-cycle, it continues suppressing the hypothalamic-pituitary axis through non-receptor pathways. Exemestane eliminates the estrogen source via irreversible aromatase inactivation, giving SERMs a corrected hormonal environment in which to stimulate gonadotropin release — a combined approach supported by clinical PCT literature.

How long does testosterone axis recovery typically take when using Exemestane in PCT?

Recovery duration varies with cycle length, compounds used, and individual HPT axis sensitivity. In controlled clinical studies, measurable LH and FSH recovery has been observed within 4–6 weeks of structured PCT that includes an AI component. Most practitioners run Exemestane for 2–4 weeks within a standard 4–6 week total PCT window, tapering dose as estradiol normalises toward mid-range reference values.

Can Supo-Aromasin 25mg tablets be split for lower doses during PCT?

Yes — the 25 mg tablet can be split to achieve a 12.5 mg dose, which is a commonly used PCT Exemestane increment for athletes who want conservative estrogen management or are combining with a SERM. Because Beligas confirms uniform content via HPLC, splitting produces predictable half-doses rather than the variable fractions possible with tablets of unverified uniformity.

How discreet is the packaging of Supo-Aromasin 50 tablets, and what is the shelf form?

Supo-Aromasin is supplied as a 50-tablet blister or sealed container with no external branding identifying the pharmacological category of the product. The compact 50-tablet format fits standard postal dimensions, supports discreet delivery, and provides a sufficient supply for a complete multi-week PCT Exemestane protocol without requiring multiple separate orders. (2) angle_used

Manufacturer

Beligas Pharmaceuticals traces its operational identity to a founding decision that shaped every subsequent product release: documentation first, distribution second. Before any Beligas tablet reaches a customer, an independently verifiable release certificate must exist for that specific lot — a practice the company embedded in its standard operating procedures from its earliest days in the pharmaceutical-grade performance supplement sector. For Supo-Aromasin, that founding principle carries particular weight: Exemestane is a compound where dosing precision during the PCT window directly determines whether the hormonal axis recovers on schedule or stalls. The infrastructure behind each Supo-Aromasin release reflects this: raw Exemestane API is evaluated against pharmacopoeial reference standards, tablet production occurs under GMP (Good Manufacturing Practice) conditions with environmental and process controls documented at each stage, and the finished tablet is subjected to HPLC quantification before a batch number is assigned a release status. Beligas also applies LAL (Limulus Amebocyte Lysate) endotoxin screening to incoming raw materials — a step that speaks to a quality-release philosophy extending beyond the active ingredient alone. This layered, documentation-anchored approach reflects a brand history built on the premise that athletes using these products for hormonally sensitive applications — post-cycle recovery above all — deserve the same analytical rigour applied in regulated pharmaceutical manufacturing.